Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy | Synapse

June 4, 2021Open Access

An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

-Lu or close analogs may provide limited and acceptable toxicity while retaining efficacy in management of prostate cancer.

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Mease et al. (Fri,) studied this question.

synapsesocial.com/papers/6a01138564548b97a42d98fb https://doi.org/https://doi.org/10.2967/jnumed.121.262098

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Photoinduced energy transfer in associated, but noncovalently-linked photosynthetic model systems.1995 · 336 citations
2Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?2019 · 123 citations
3Blocking [211At]Astatide Accumulation in Normal Tissues: Preliminary Evaluation of Seven Potential Compounds1998 · 76 citations
4Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated α-Linked Acidic Dipeptidase1996 · 256 citations
5Efficacy and safety of <sup>225</sup>Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients2020 · 153 citations